Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4111 | Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki | 1.00 |
| drug4119 | Two doses of placebo at the schedule of day 0,28 Wiki | 1.00 |
| drug3446 | SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000073397 | Occupational Stress NIH | 0.32 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This study is a randomized, double-blinded, and placebo controlled phase 1&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults aged≥60 years.
Description: Incidence of adverse reactions after each dose vaccination
Measure: Safety index-incidence of adverse reactions Time: Day 0-28 after each dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or ≥4 fold increase from baseline.
Measure: Immunogenicity index-seroconversion rates of neutralizing antibody Time: The 30th day after the second dose vaccinationDescription: SAE will be collected throughout the clinical trial
Measure: Safety index-incidence of serious adverse events Time: From the beginning of the vaccination to 12 months after the second dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method, and subjects with a antibody titer ≥1:8 will defined as seropositive.
Measure: Immunogenicity index-seropositive rates of neutralizing antibody Time: The 30th day and the 12 month after the second dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method
Measure: Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody Time: The 30th day and the 12 month after the second dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method. Ratio of post-vaccination titer divided by baseline titer will be calculated.
Measure: Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody Time: The 30th day after the second dose vaccinationThis study is a randomized, double-blinded, and placebo controlled phase 1&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy children and adolescents aged 3-17 years
Description: Incidence of adverse reactions after each dose vaccination.
Measure: Safety index-incidence of adverse reactions Time: Day 0-28 after each dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or ≥4 fold increase from baseline.
Measure: Immunogenicity index-seroconversion rates of neutralizing antibody Time: The 28th day after the second dose vaccinationDescription: SAE will be collected throughout the clinical trial.
Measure: Safety index-incidence of serious adverse events Time: From the beginning of the vaccination to 12 months after the second dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method, and subjects with a antibody titer ≥1:8 will defined as seropositive.
Measure: Immunogenicity index-seropositive rates of neutralizing antibody Time: The 28th day after each dose vaccination and the 12 month after the second dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method.
Measure: Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody Time: The 28th day after each dose vaccination and the 12 month after the second dose vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method. Ratio of post-vaccination titer divided by baseline titer will be calculated.
Measure: Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody Time: The 28th day after each dose vaccination and the 12 month after the second dose vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports